A Broad Spectrum of Antibiotic Dealmaking
Executive Summary
Most of the recent antibiotic deals don't stem from the most obvious problem--antibiotic resistance. Still looking for broad-spectrum antibiotics, drug firms are increasingly willing to out-license their smaller-market produts to smaller companies. We list more than a dozen recent deals in anti-infectives.